328 related articles for article (PubMed ID: 8105939)
21. Effect of oral calcitriol pulse therapy on the lipid, calcium, and glucose homeostasis of hemodialysis-patients: its safety in a combination with oral calcium carbonate.
Khajehdehi P; Taheri S
J Ren Nutr; 2003 Apr; 13(2):78-83. PubMed ID: 12671829
[TBL] [Abstract][Full Text] [Related]
22. Improvement of secondary hyperparathyroidism and reduction of the set point of calcium after intravenous calcitriol.
Malberti F; Surian M; Cosci P
Kidney Int Suppl; 1993 Jun; 41():S125-30. PubMed ID: 8320905
[TBL] [Abstract][Full Text] [Related]
23. A crossover comparison of intermittent oral and intravenous administration of calcitriol on the parathyroid hormone concentration in hemodialysis patients.
Peng SJ; Yang CS; Ferng SH; Chen LY
Miner Electrolyte Metab; 1997; 23(1):13-8. PubMed ID: 9058364
[TBL] [Abstract][Full Text] [Related]
24. A randomized trial comparing 1.25 mmol/l calcium dialysate to 1.75 mmol/l calcium dialysate in CAPD patients.
Johnson DW; Rigby RJ; McIntyre HD; Brown A; Freeman J
Nephrol Dial Transplant; 1996 Jan; 11(1):88-93. PubMed ID: 8649658
[TBL] [Abstract][Full Text] [Related]
25. Pulse oral calcitriol for the treatment of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis: preliminary observations.
Martin KJ; Ballal HS; Domoto DT; Blalock S; Weindel M
Am J Kidney Dis; 1992 Jun; 19(6):540-5. PubMed ID: 1595702
[TBL] [Abstract][Full Text] [Related]
26. [A trial of suppressing secondary hyperparathyroidism by oral high dose therapy of 1, 25-dihydroxyvitamin D3].
Shigematsu T; Kawaguchi Y; Unemura S; Suzuki M; Yamamoto H; Morita T; Momose M; Ogawa A; Nakayama M; Miyahara T
Nihon Jinzo Gakkai Shi; 1989 Apr; 31(4):393-401. PubMed ID: 2787433
[TBL] [Abstract][Full Text] [Related]
27. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
Greenbaum LA; Benador N; Goldstein SL; Paredes A; Melnick JZ; Mattingly S; Amdahl M; Williams LA; Salusky IB
Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
[TBL] [Abstract][Full Text] [Related]
28. Limitations of pulse oral calcitriol therapy in continuous ambulatory peritoneal dialysis patients.
Bechtel U; Mücke C; Feucht HE; Schiffl H; Sitter T; Held E
Am J Kidney Dis; 1995 Feb; 25(2):291-6. PubMed ID: 7847357
[TBL] [Abstract][Full Text] [Related]
29. [Intravenous calcitriol in the treatment of the refractory secondary hyperparathyroidism of terminal chronic kidney failure].
Almirall J; Torregrosa V; Arrizabalaga P; Cases A; Oliva J
Med Clin (Barc); 1994 Mar; 102(9):325-8. PubMed ID: 8164458
[TBL] [Abstract][Full Text] [Related]
30. A controlled trial of the early treatment of secondary hyperparathyroidism with calcitriol in hemodialysis patients.
Delmez JA; Kelber J; Norwood KY; Giles KS; Slatopolsky E
Clin Nephrol; 2000 Oct; 54(4):301-8. PubMed ID: 11076106
[TBL] [Abstract][Full Text] [Related]
31. Intravenous 1,25(OH)2D therapy increases the intact parathyroid hormone secretion set point in hemodialyzed patients.
Brossard JH; Roy L; Lepage R; Gascon-Barré M; D'Amour P
Miner Electrolyte Metab; 1997; 23(1):25-32. PubMed ID: 9058366
[TBL] [Abstract][Full Text] [Related]
32. Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism.
Jamaluddin EJ; Gafor AH; Yean LC; Cader R; Mohd R; Kong NC; Shah SA
Clin Exp Nephrol; 2014 Jun; 18(3):507-14. PubMed ID: 23903802
[TBL] [Abstract][Full Text] [Related]
33. Secondary hyperparathyroidism in CAPD patients: its suppressibility with high doses of calcitriol.
Felipe C; Miranda B; Selgas R; Martinez ME; Miguel JL; Moreno F; Caparros G; Torre A; Sicilia LS
Adv Perit Dial; 1990; 6():238-41. PubMed ID: 1982816
[TBL] [Abstract][Full Text] [Related]
34. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients.
Kiattisunthorn K; Wutyam K; Indranoi A; Vasuvattakul S
Nephrology (Carlton); 2011 Mar; 16(3):277-84. PubMed ID: 21342321
[TBL] [Abstract][Full Text] [Related]
35. [Treatment of secondary hyperparathyroidisms of predialysis chronic renal failure with low doses of 1.25(OH)2D3].
Kato N; Kasai K; Kawaguchi Y; Yamamoto H; Shigematu T; Sakai O
Nihon Jinzo Gakkai Shi; 1995 Oct; 37(10):543-8. PubMed ID: 7474506
[TBL] [Abstract][Full Text] [Related]
36. High prevalence of secondary hyperparathyroidism in chronic kidney disease patients on dialysis in Argentina.
Douthat WG; Castellano M; Berenguer L; Guzmán MA; de Arteaga J; Chiurchiu CR; Massari PU; Garay G; Capra R; de La Fuente JL
Nefrologia; 2013; 33(5):657-66. PubMed ID: 24089157
[TBL] [Abstract][Full Text] [Related]
37. Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: effects on bone mineral metabolism. Collaborators of the Multicenter Study Group.
Weinreich T; Ritz E; Passlick-Deetjen J
Perit Dial Int; 1996; 16(3):260-8. PubMed ID: 8761540
[TBL] [Abstract][Full Text] [Related]
38. Pulse oral versus pulse intraperitoneal calcitriol: a comparison of efficacy in the treatment of hyperparathyroidism and renal osteodystrophy in peritoneal dialysis patients.
Gadallah MF; Arora N; Torres C; Ramdeen G; Schaeffer-Pautz A; Moles K
Adv Perit Dial; 2000; 16():303-7. PubMed ID: 11045316
[TBL] [Abstract][Full Text] [Related]
39. No difference in intestinal strontium absorption after oral or IV calcitriol in children with secondary hyperparathyroidism. The European Study Group on Vitamin D in Children with Renal Failure.
Ardissino G; Schmitt CP; Bianchi ML; Daccò V; Claris-Appiani A; Mehls O
Kidney Int; 2000 Sep; 58(3):981-8. PubMed ID: 10972662
[TBL] [Abstract][Full Text] [Related]
40. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
